Tacrolimus 0.03/0.1% ointment — Membership Pricing
Tacrolimus 0.03/0.1% ointment is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Tacrolimus 0.03/0.1% ointment Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $31.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Tacrolimus 0.03/0.1% ointment
Tacrolimus 0.03/0.1% ointment is a prescription medication. Ask your doctor if Tacrolimus 0.03/0.1% ointment is right for you.
Other strengths and forms of Tacrolimus
Conditions Treated with Tacrolimus 0.03/0.1% ointment
How to Check Tacrolimus 0.03/0.1% ointment Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Tacrolimus 0.03/0.1% ointment at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Eczema / Atopic Dermatitis
What Tacrolimus 0.03/0.1% ointment is approved for (FDA label)
Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING, WARNINGS and PRECAUTIONS: Pediatric Use).
Source: Read the full FDA label on DailyMed. Label effective date: April 15, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Tacrolimus 0.03/0.1% ointment (FDA label)
No phototoxicity and no photoallergenicity were detected in clinical studies with 12 and 216 normal volunteers, respectively. One out of 198 normal volunteers showed evidence of sensitization in a contact sensitization study. In three 12 week randomized vehicle-controlled studies and four safety studies, 655 and 9,163 patients respectively, were treated with tacrolimus ointment. The duration of follow-up for adult and pediatric patients in the safety studies is tabulated below.
Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Tacrolimus 0.03/0.1% ointment (FDA label)
Tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.
Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Tacrolimus 0.03/0.1% ointment (FDA label)
Formal topical drug interaction studies with tacrolimus ointment have not been conducted. Based on its extent of absorption, interactions of tacrolimus ointment with systemically administered drugs are unlikely to occur but cannot be ruled out (see CLINICAL PHARMACOLOGY ). The concomitant administration of known CYP3A4 inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.
Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.